Board Of Directors
Graeme Kaufman
Non Executive Chairman
Graeme has wide ranging, hands on experience across the biotechnology sector, spanning technical, commercial and financial areas. He has significant Board experience with ASX listed companies, in both executive and non-executive roles. He spent 32 years in various roles at CSL Limited, Australia’s largest biopharmaceutical company and was one of the driving forces behind the listing of the company on the ASX.He has also held senior roles since that time at companies such as Circadian Technologies, Amrad and Mesoblast.Graeme is currently Chairman of Bionomic Limited and a non-executive director of Cellmid Limited.
Geoffrey F Lord
Deputy Chairman
BEco (Hons), MBA (Distn), ASSA, AICD
Formerly Chief Executive and Deputy Chairman of Elders Resources Limited. Current Directorships: Presently Chairman and Chief Executive of Belgravia Group Pty Ltd, Executive Chairman of UXC Limited, Chairman of LCM Litigation Fund, Maxitrans Industries Limited, KLM Group Limited and Northern Energy Corporation Limited
Responsibilities: Non executive. Member of Nomination and Remuneration Committees.
Dr Graeme L Blackman
BSc(Hons), PhD, FRACI, FTSE
Formerly Professor of Pharmaceutical Chemistry, Victorian College of Pharmacy. Extensive experience in research and development and commercial scientific consulting.
Responsibilities - Executive Chairman of the Board, Member of Nomination Committee, Member of the Remuneration Committee.
Dr. Blackman is the founder of IDT and majority shareholder.
He has over 25 years experience in the international pharmaceutical
industry including the research and development sector. Dr. Blackman
is a member of key government and pharmaceutical industry policy
committees, and a board member of Medicines Australia. He is also
the Chairman of the Pharmaceutical Industry Action Agenda.
Responsibilities - Member of Nomination Committee, Member of the
Remuneration Committee. Dr. Blackman is the founder of IDT and majority
shareholder. He has over 25 years experience in the international
pharmaceutical industry including the research and development sector.
Dr. Blackman is a member of key government and pharmaceutical industry
policy committees, and a board member of Medicines Australia. He
is also the Chairman of the Pharmaceutical Industry Action Agenda.
Dr Roger Aston
BSc (Hons), PhD
Formerly Executive Chairman of Mayne Pharma Group Limited (acquisition of Mayne by Halcygen) and CEO of Mayne Pharma Group Limited.
During his career, Roger Aston has been closely involved in start-up companies and major pharmaceutical companies. He has had a 'hands on'; role in company restructuring, improving effectiveness and productivity in both small and significant businesses. Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, preparation of prospects for a public offering, and a network of contacts within the pharmaceutical, banking and stock broking sectors.
Responsibilities - Non executive. Member of Nomination Committee.
David Williams
B.Ec (Hons), M.Ec, FAICD
Managing Director Kidder Williams Ltd
Chairman Medical Developments International Ltd
Previously David was the Managing Director of Mariner Corporate Finance, Managing Director of Challenger Corporate Finance, Head of the Melbourne corporate finance office of SG Hambros, Head of M&A at ANZ McCaughan, and Head of M&A at Arthur Andersen.
Responsibilities - Non executive. Member of Audit Committees.
Reo Shigeno
Reo is the Chief Financial Officer of Healthy Clinical research Pty Ltd, a subsidiary of I'rom Holdings Group where he manages I’rom Group’s investment portfolios.
He has in the past been a Private Banker with ANZ Private Bank and a Japanese Relationship Manager with the ANZ Banking Group.